File Download

There are no files associated with this item.

Supplementary

Conference Paper: Xelox causes less disabling peripheral neuropathy than FOLFOX4 for Chinese colorectal cancer patients.

TitleXelox causes less disabling peripheral neuropathy than FOLFOX4 for Chinese colorectal cancer patients.
Authors
Issue Date2007
PublisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.asco.org/ASCOv2/Meetings/ASCO+Annual+Meeting
Citation
A S C O Annual Meeting Proceedings, 2007, v. 43, p. 632 How to Cite?
AbstractBackground: Infusional 5-FU plus leucovorin and oxaliplatin (FOLFOX4) is an efficacious treatment for colorectal cancer patients in both the adjuvant and metastatic settings. However, around 10% of FOLFOX4 patients will develop with disabling grade 3–4 neuropathy. Recent phase II studies have demonstrated that oral capecitabine in combination with oxaliplatin (XELOX) is as least as effective as FOLFOX4 for colorectal cancer. In this study, we assessed the toxicities of XELOX in Chinese colorectal cancer patients. Methods: Patients who received XELOX at Queen Mary Hospital, Hong Kong between November 2004 and November, 2006 were analyzed. Toxicities were graded by the National Cancer Institute common toxicity system. Results: Thirty-five patients received XELOX on an outpatient basis during the study period: Twenty-four as adjuvant therapy and 11 as treatment for metastatic disease. The most common side effect was grade 1–2 peripheral neuropathy which occurred in 77% of patients. No grade 3–4 neuropathy was reported. Grade 1–2 diarrhea and palmar-plantar erythrodysesthesia (PPE) also occurred in 40 % and 37 % of patients, respectively. The commonest grade 3 toxicities was diarrhea which occurred in 17% of the patients followed by 9% of patients experienced grade 3 PPE. No grade 4 toxicities were reported in our patient’s cohort. Overall, only one (3%) patient had neutropenic sepsis and 36% of patients required 20% reduction in drug dosage. No treatment related death was reported. Conclusions: Our study suggests that XELOX is a well-tolerated and convenient treatment regime. Although mild neuropathy is common in patients receiving XELOX, it causes far less disabling neuropathy than FOLFOX4 in Chinese metastatic colorectal cancer patients.
Persistent Identifierhttp://hdl.handle.net/10722/78359

 

DC FieldValueLanguage
dc.contributor.authorYau, Ten_HK
dc.contributor.authorChan, Pen_HK
dc.contributor.authorTsang, Jen_HK
dc.contributor.authorLiang, RHSen_HK
dc.contributor.authorEpstein, Ren_HK
dc.date.accessioned2010-09-06T07:42:00Z-
dc.date.available2010-09-06T07:42:00Z-
dc.date.issued2007en_HK
dc.identifier.citationA S C O Annual Meeting Proceedings, 2007, v. 43, p. 632en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78359-
dc.description.abstractBackground: Infusional 5-FU plus leucovorin and oxaliplatin (FOLFOX4) is an efficacious treatment for colorectal cancer patients in both the adjuvant and metastatic settings. However, around 10% of FOLFOX4 patients will develop with disabling grade 3–4 neuropathy. Recent phase II studies have demonstrated that oral capecitabine in combination with oxaliplatin (XELOX) is as least as effective as FOLFOX4 for colorectal cancer. In this study, we assessed the toxicities of XELOX in Chinese colorectal cancer patients. Methods: Patients who received XELOX at Queen Mary Hospital, Hong Kong between November 2004 and November, 2006 were analyzed. Toxicities were graded by the National Cancer Institute common toxicity system. Results: Thirty-five patients received XELOX on an outpatient basis during the study period: Twenty-four as adjuvant therapy and 11 as treatment for metastatic disease. The most common side effect was grade 1–2 peripheral neuropathy which occurred in 77% of patients. No grade 3–4 neuropathy was reported. Grade 1–2 diarrhea and palmar-plantar erythrodysesthesia (PPE) also occurred in 40 % and 37 % of patients, respectively. The commonest grade 3 toxicities was diarrhea which occurred in 17% of the patients followed by 9% of patients experienced grade 3 PPE. No grade 4 toxicities were reported in our patient’s cohort. Overall, only one (3%) patient had neutropenic sepsis and 36% of patients required 20% reduction in drug dosage. No treatment related death was reported. Conclusions: Our study suggests that XELOX is a well-tolerated and convenient treatment regime. Although mild neuropathy is common in patients receiving XELOX, it causes far less disabling neuropathy than FOLFOX4 in Chinese metastatic colorectal cancer patients.-
dc.languageengen_HK
dc.publisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.asco.org/ASCOv2/Meetings/ASCO+Annual+Meetingen_HK
dc.relation.ispartofA S C O Annual Meeting Proceedingsen_HK
dc.titleXelox causes less disabling peripheral neuropathy than FOLFOX4 for Chinese colorectal cancer patients.en_HK
dc.typeConference_Paperen_HK
dc.identifier.emailLiang, RHS: rliang@hku.hken_HK
dc.identifier.emailEpstein, R: repstein@hku.hken_HK
dc.identifier.authorityLiang, RHS=rp00345en_HK
dc.identifier.authorityEpstein, R=rp00501en_HK
dc.identifier.hkuros131729en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats